Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosfomycin/metronidazole - Reponex Pharmaceuticals

Drug Profile

Fosfomycin/metronidazole - Reponex Pharmaceuticals

Alternative Names: RNX-051

Latest Information Update: 05 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Reponex Pharmaceuticals
  • Class Anti-infectives; Antibacterials; Antiprotozoals; Epoxy compounds; Esters; Nitroimidazoles; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Phosphoric Acids; Radiosensitisers; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell wall inhibitors; DNA synthesis inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Bacterial infections

Most Recent Events

  • 01 Jul 2023 Reponex Pharmaceuticals in collaboration with Zealand University Hospital completes a Phase-II clinical trial in Bacterial infections in Denmark (Parenteral) (EudraCT 2019-000131-51) (NCT04312360)
  • 14 Oct 2022 Fosfomycin/metronidazole is still in phase II trials for Bacterial infections in Denmark (NCT04312360)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top